Integration of tissue metabolomics, transcriptomics and immunohistochemistry revealsERG-and gleason score-specific metabolomic alterations in prostate cancer

Abstract

// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Sebastian Meller1,*, Hellmuth-A Meyer2,*, Bianca Bethan3, Dimo Dietrich1, Sandra González Maldonado3, Michael Lein4,5, Matteo Montani6, Regina Reszka7, Philipp Schatz7, Erik Peter3, Carsten Stephan4,8, Klaus Jung4,8, Beate Kamlage3,** and Glen Kristiansen1,** 1 Institute of Pathology, University Hospital of Bonn, Bonn, Germany 2 Campus Wilhelminenhof, University of Applied Sciences, Berlin, Germany 3 metanomics GmbH, Berlin, Germany 4 Berlin Institute for Urologic Research, Berlin, Germany 5 Department of Urology, University Teaching Hospital, Offenbach, Germany 6 Institute of Pathology, University of Bern, Bern, Switzerland 7 Metanomics Health GmbH, Berlin, Germany 8 Department of Urology, University Hospital Charité, Berlin, Germany * joint first authors ** joint senior authors Correspondence to: Glen Kristiansen, email: // <![CDATA[ mail("glen.kristiansen","ukb.uni-bonn",19,"") // ]]> keywords: prostate cancer, metabolites, ERG translocation, cholesterol, fatty acid Received: July 14, 2015 Accepted: November 15, 2015 Published: November 23, 2015